Direct plan
Data as on 30-10-2026
Nippon India Nifty Pharma ETF is a mutual fund run by Nippon India Mutual Fund. On 30-09-2026, it managed ₹1,736 Cr of investors' money. In the 3 years to 30-10-2026, it returned 22.9% a year. Its benchmark, Nifty Pharma TRI, returned 23.3% a year over the same 3 years.
NAV on 30-10-2026: Direct Plan ₹27.89 (up 1.55% that day).
Returns as on 30-10-2026. Up to one year they are absolute returns. Longer periods are a rate per year.
| Period | 1M | 3M | 6M | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|---|---|---|
| This fund (Direct) | +2.58% | +2.95% | +16.84% | +22.08% | +22.94% | +14.91% | -- |
| Nifty Pharma TRI | +2.60% | +3.01% | +16.99% | +22.38% | +23.26% | +15.17% | +9.59% |
| Category average | -- | -- | -- | -- | -- | -- | -- |
| Best in category | -- | -- | -- | -- | -- | -- | -- |
| Worst in category | -- | -- | -- | -- | -- | -- | -- |
| Rank in category | -- | -- | -- | -- | -- | -- | -- |
No category comparison is shown: this fund's category is too broad to compare, or has fewer than five funds.
| Year | Direct | Nifty Pharma TRI |
|---|---|---|
| 2026to date | +19.82% | +20.06% |
| 2025 | −2.46% | −2.25% |
| 2024 | +39.59% | +40.03% |
| 2023 | +34.44% | +34.76% |
| 2022 | −10.86% | −10.73% |
The return of every holding period in the fund's history, not only the one that ends today
Rolling returns
Each point is the yearly return of one 3-year holding period, plotted on the day it ended. There are 573 periods, one for each trading day from 08-07-2024 to 30-10-2026.
Nippon India Nifty Pharma ETF (Direct)
Nifty Pharma TRI
Every holding period at a glance
| Period | Periods | Median | Lowest | Highest | With a loss | Benchmark median | Beat benchmark |
|---|---|---|---|---|---|---|---|
| 1 year | 1,066 | 13.2% | −15.3% | 65.2% | 26% | 13.4% | 1% |
| 2 years | 820 | 19.4% | −1.8% | 38.5% | 2% | 19.7% | 1% |
| 3 years | 573 | 20.5% | 12.3% | 27.7% | 0% | 20.8% | 0% |
| 5 years | 80 | 13.5% | 12.4% | 14.9% | 0% | 13.8% | 0% |
Every SIP holding period at a glance
| Period | Periods | Median | Lowest | Highest | With a loss | Benchmark median | Beat benchmark |
|---|---|---|---|---|---|---|---|
| 1 year | 52 | 11.1% | −18.9% | 65.4% | 29% | 11.4% | 0% |
| 2 years | 40 | 16.7% | 2.1% | 49.0% | 0% | 17.0% | 0% |
| 3 years | 28 | 19.3% | 11.4% | 34.1% | 0% | 19.6% | 0% |
Lumpsum: the yearly rate (CAGR) from the NAV on a period's first day to the NAV on its last. SIP: the XIRR of the monthly instalments and their value on the last day. "With a loss" counts the periods that ended below the money put in. "Beat benchmark" counts the periods in which the fund did better than Nifty Pharma TRI over the same days. Past returns do not promise future returns.
How much it swings, and the falls an investor had to sit through
Risk and return
| Measure | Nippon India Nifty Pharma ETF (Direct)This fund | Nifty Pharma TRI |
|---|---|---|
| Return (CAGR) | +22.08% | +22.38% |
| Standard deviation | 14.13% | 14.09% |
| Sharpe ratio | 1.19 | 1.22 |
| Sortino ratio | 1.86 | 1.89 |
| Maximum drawdown | −7.5% (01-02-2026) | −7.5% (01-02-2026) |
| Beta | 1.00 | 1.00 |
| Alpha | −0.28% | 0.00% |
From daily NAVs, 30-10-2025 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta: 1 moves with the benchmark, below 1 moves less. Alpha: return beyond what its beta explains, a year.
| Measure | Nippon India Nifty Pharma ETF (Direct)This fund | Nifty Pharma TRI |
|---|---|---|
| Return (CAGR) | +22.94% | +23.26% |
| Standard deviation | 15.07% | 15.07% |
| Sharpe ratio | 1.12 | 1.14 |
| Sortino ratio | 1.63 | 1.66 |
| Maximum drawdown | −16.6% (28-02-2025) | −16.5% (28-02-2025) |
| Beta | 1.00 | 1.00 |
| Alpha | −0.30% | 0.00% |
From daily NAVs, 30-10-2023 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta: 1 moves with the benchmark, below 1 moves less. Alpha: return beyond what its beta explains, a year.
| Measure | Nippon India Nifty Pharma ETF (Direct)This fund | Nifty Pharma TRI |
|---|---|---|
| Return (CAGR) | +14.91% | +15.17% |
| Standard deviation | 14.93% | 14.94% |
| Sharpe ratio | 0.61 | 0.63 |
| Sortino ratio | 0.89 | 0.91 |
| Maximum drawdown | −17.7% (13-03-2023) | −17.6% (13-03-2023) |
| Beta | 1.00 | 1.00 |
| Alpha | −0.25% | 0.00% |
From daily NAVs, 29-10-2021 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta: 1 moves with the benchmark, below 1 moves less. Alpha: return beyond what its beta explains, a year.
| Measure | Nippon India Nifty Pharma ETF (Direct)This fund | Nifty Pharma TRI |
|---|---|---|
| Return (CAGR) | +13.22% | +13.49% |
| Standard deviation | 15.07% | 15.09% |
| Sharpe ratio | 0.50 | 0.52 |
| Sortino ratio | 0.72 | 0.75 |
| Maximum drawdown | −21.0% (13-03-2023) | −20.8% (13-03-2023) |
| Beta | 1.00 | 1.00 |
| Alpha | −0.26% | 0.00% |
From daily NAVs, 06-07-2021 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta: 1 moves with the benchmark, below 1 moves less. Alpha: return beyond what its beta explains, a year.
Drawdowns
How far below its previous high each one was on every day: the falls an investor had to sit through. 0% means it was at a new high.
Nippon India Nifty Pharma ETF (Direct)
Nifty Pharma TRI
| Worst fall | High before it | Bottom | Back at the high | Time to climb back | Below its high today | |
|---|---|---|---|---|---|---|
| Nippon India Nifty Pharma ETF (Direct) | −21.0% | 04-10-2021 | 13-03-2023 | 27-07-2023 | 4 months | −0.26% |
| Nifty Pharma TRI | −20.8% | 04-10-2021 | 13-03-2023 | 27-07-2023 | 4 months | −0.23% |
From the Direct plan's daily NAV since 06-07-2021, adjusted for unit splits, and Nifty Pharma TRI over the same days. "Time to climb back" runs from the bottom to the first day back at the old high.
What each plan charges a year, in force from 01-09-2026
| Plan | Base expense ratio | Brokerage | Transaction costs | Levies and GST | Total expense ratio |
|---|---|---|---|---|---|
| Direct | 0.18% | 0.00% | 0.00% | 0.05% | 0.23% |
The expense ratio comes out of the fund's assets every day, so every return on this page is already after it. Base expense ratio: the fund house's own fee. The total adds brokerage, the cost of executing trades, and statutory levies with GST. From AMFI's expense ratio file.
What a one-time or monthly investment in this fund would be worth today, from its own NAV history
Growth of an investment
₹10,000 on the first trading day of every month, from 06-07-2021 to 30-10-2026: 64 instalments, ₹6,40,000 in all.
| Investment | Invested | Value now | Gain | Return a year |
|---|---|---|---|---|
| Direct planNippon India Nifty Pharma ETF (Direct) | ₹6,40,000 | ₹10,43,720 | ₹4,03,720 | 18.4% |
| Nifty Pharma TRI | ₹6,40,000 | ₹10,51,495 | ₹4,11,495 | 18.6% |
Direct planNippon India Nifty Pharma ETF (Direct)
Nifty Pharma TRI
Amount invested
From each plan's published NAV (Growth option), the benchmark's TRI, over the same days. Return a year: XIRR for a SIP, CAGR for a lumpsum, shown for a year or more. It does not include exit load, stamp duty or tax. Past returns do not promise future returns.
Asset allocation as on 30-09-2026
99.9%Equity
| Asset | Fund |
|---|---|
| Equity | 99.9% |
| Cash and others | 0.1% |
| Market cap | Fund |
|---|---|
| Large Cap | 46.3% |
| Mid Cap | 46.1% |
| Small Cap | 7.5% |
Share of the whole fund. Groups follow AMFI's latest list, as SEBI defines them: Large Cap is the 100 largest companies, Mid Cap the next 150, Small Cap the rest.
Sector allocation of the fund's stocks as on 30-09-2026
Pharmaceuticals & Biotechnology99.9%
| Sector | July 2026 | August 2026 | September 2026 | Change |
|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 99.8% | 100.0% | 99.9% | +0.1% |
Each sector's share of the fund at the end of each month. The five largest sectors of September 2026. Change: from July 2026 to September 2026, in % of the fund.
As on 30-09-2026 · 20 holdings · from the fund house's monthly portfolio
| Holdings | Sector | Weight% | Holdings trend | 1M change |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | Pharmaceuticals & Biotechnology | 19.50% | +1.3% | |
| Divi's Laboratories Limited | Pharmaceuticals & Biotechnology | 11.97% | +1.3% | |
| Laurus Labs Limited | Pharmaceuticals & Biotechnology | 7.82% | +1.4% | |
| Cipla Limited | Pharmaceuticals & Biotechnology | 7.68% | +1.3% | |
| Dr. Reddy's Laboratories Limited | Pharmaceuticals & Biotechnology | 7.62% | +1.3% | |
| Torrent Pharmaceuticals Limited | Pharmaceuticals & Biotechnology | 7.16% | +1.6% | |
| Lupin Limited | Pharmaceuticals & Biotechnology | 5.00% | +1.3% | |
| Aurobindo Pharma Limited | Pharmaceuticals & Biotechnology | 4.69% | +1.1% | |
| Glenmark Pharmaceuticals Limited | Pharmaceuticals & Biotechnology | 3.56% | +1.3% | |
| Alkem Laboratories Limited | Pharmaceuticals & Biotechnology | 3.16% | +4.4% | |
| Zydus Lifesciences Limited | Pharmaceuticals & Biotechnology | 2.92% | +0.3% | |
| Mankind Pharma Limited | Pharmaceuticals & Biotechnology | 2.88% | +1.4% | |
| IPCA Laboratories Limited | Pharmaceuticals & Biotechnology | 2.71% | +1.3% | |
| Biocon Limited | Pharmaceuticals & Biotechnology | 2.62% | −1.1% | |
| Gland Pharma Limited | Pharmaceuticals & Biotechnology | 2.34% | +1.3% | |
| Sai Life Sciences Limited | Pharmaceuticals & Biotechnology | 2.14% | +1.5% | |
| Wockhardt Limited | Pharmaceuticals & Biotechnology | 1.77% | +1.3% | |
| Ajanta Pharma Limited | Pharmaceuticals & Biotechnology | 1.67% | +9.6% | |
| Abbott India Limited | Pharmaceuticals & Biotechnology | 1.43% | +1.3% | |
| Piramal Pharma Limited | Pharmaceuticals & Biotechnology | 1.30% | +1.1% |
All changes are between August 2026 and September 2026
| Sun Pharmaceutical Industries Limited | Added | +1.3% | 19.50% |
|---|---|---|---|
| Divi's Laboratories Limited | Added | +1.3% | 11.97% |
| Cipla Limited | Added | +1.3% | 7.68% |
| Laurus Labs Limited | Added | +1.4% | 7.82% |
| Dr. Reddy's Laboratories Limited | Added | +1.3% | 7.62% |
| Torrent Pharmaceuticals Limited | Added | +1.6% | 7.16% |
| Lupin Limited | Added | +1.3% | 5.00% |
| Aurobindo Pharma Limited | Added | +1.1% | 4.69% |
| Glenmark Pharmaceuticals Limited | Added | +1.3% | 3.56% |
| Alkem Laboratories Limited | Added | +4.4% | 3.16% |
| Zydus Lifesciences Limited | Added | +0.3% | 2.92% |
| Biocon Limited | Reduced | −1.1% | 2.62% |
| Mankind Pharma Limited | Added | +1.4% | 2.88% |
| IPCA Laboratories Limited | Added | +1.3% | 2.71% |
| Gland Pharma Limited | Added | +1.3% | 2.34% |
| Sai Life Sciences Limited | Added | +1.5% | 2.14% |
| Wockhardt Limited | Added | +1.3% | 1.77% |
| Ajanta Pharma Limited | Added | +9.6% | 1.67% |
| Abbott India Limited | Added | +1.3% | 1.43% |
| Piramal Pharma Limited | Added | +1.1% | 1.30% |
No stocks in this group for September 2026.
A change is counted by the number of shares the fund holds, not by price. A stock can become a smaller part of the fund in a month when the fund bought more of it, if its price fell. Debt papers are left out.
Funds with the most similar portfolios, across every fund house and category
| Fund | Overlap | Holdings in common | |
|---|---|---|---|
| ICICI Prudential Nifty Pharma Index FundIndex · ICICI Prudential | 99.9% | 20 | Compare |
| DSP Nifty Healthcare Index FundIndex · DSP | 81.2% | 16 | Compare |
| Axis NIFTY Healthcare ETFETF · Axis | 81.1% | 16 | Compare |
| ICICI Prudential Nifty Healthcare ETFETF · ICICI Prudential | 81.1% | 16 | Compare |
| Aditya Birla Sun Life Nifty Healthcare ETFETF · Aditya Birla Sun Life | 81.1% | 16 | Compare |
| DSP Nifty Healthcare ETFETF · DSP | 81.1% | 16 | Compare |
| Mirae Asset Nifty 500 Healthcare ETFETF · Mirae Asset | 69.0% | 20 | Compare |
| Mirae Asset Healthcare FundThematic · Mirae Asset | 63.9% | 15 | Compare |
Overlap: for each holding both funds own, the smaller of its two weights, added up. 40% means 40% of each fund's money sits in positions the other also holds. From each fund's latest monthly portfolio, matched by ISIN. Cash and hedged positions are left out. Funds that overlap under 10% are not listed. A high overlap does not make two funds the same: their costs, lock-in and category can differ.
Fund facts from the scheme summary document
Rules in force from 23-07-2024 (Finance Act 2024). Tax depends on your own income; this is general information, not tax advice.
Nippon India Nifty Pharma ETF is a mutual fund from Nippon India Mutual Fund. At the end of September 2026 it held 20 securities.
Not available
See all funds of Nippon India Mutual Fund
AUM moves with money invested or taken out, and with the value of what the fund holds.
Returns, risk, costs and the stocks they share, side by side
The Direct plan NAV is ₹27.8861, as on 30-10-2026.
The Direct plan returned +22.08% in 1 year, +22.94% a year over 3 years, +14.91% a year over 5 years. These figures are as on 30-10-2026.
The Direct plan charges 0.23% a year. This is the figure the fund house reported to AMFI, in force from 01-09-2026.
Nippon India Nifty Pharma ETF managed ₹1,736.44 Cr on 30-09-2026, as its fund house reported in its monthly portfolio.
At the end of September 2026 the largest holdings were SUNPHARMA (19.50%), DIVISLAB (11.97%), LAURUSLABS (7.82%), CIPLA (7.68%), DRREDDY (7.62%). The fund held 20 securities in all.
It added shares in 19. It reduced 1.
Through Nippon India Mutual Fund's website or app, a mutual fund distributor, or an investment platform. Choose the Direct plan to pay no distributor commission, or the Regular plan to invest through a distributor. You can invest once or through a monthly SIP.
Its benchmark is Nifty Pharma TRI. The Direct plan returned +14.91% a year over 5 years. The benchmark returned +15.17% a year over 5 years.
Sources: NAV and expense ratio from AMFI. Holdings from the fund house's monthly portfolio statement. Fund facts from its scheme summary document.
This page is information, not investment advice. Mutual fund investments are subject to market risks; read all scheme related documents carefully. Past returns do not promise future returns. Figures come from AMFI, NSE, BSE and each fund house's own documents.
Track Nippon India Nifty Pharma ETF in WealthGamma
Add this fund once. WealthGamma updates its value every day and shows it next to your stocks, gold, deposits and loans.
PAN not required · No broker linking · No OTPs